Payment overview · 2025
General Payments
$2,151.75
120 reported records · 22 companies
Healthcare provider profile · identity verified
Rajesh Agarwal, M.D.
Allopathic & Osteopathic Physicians|General Practice · MAYFIELD HEIGHTS, OH · NPI 1285618579
Verified facts
What the public records show
CMS Open Payments records show Rajesh Agarwal, M.D. received $2,151.75 in general payments during 2025 across 120 reported records.
AstraZeneca Pharmaceuticals LP accounted for 20.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 36 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo, Arexvy, Brilinta, Creon, Eliquis, Farxiga, Jardiance, Kerendia, Linzess, Lokelma, Mounjaro, Otezla, Ozempic, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 140 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Vraylar by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OTEZLA as an associated drug or biological on 177267 records involving 48600 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Otezla by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 498 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Lokelma by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 736 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 4462 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 206 claims for Trelegy Ellipta by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INVEGA SUSTENNA as an associated drug or biological on 39068 records involving 11966 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Invega Sustenna by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 687 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 736 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 273 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABILIFY MAINTENA as an associated drug or biological on 2902 records involving 986 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Abilify Maintena by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Fiasp as an associated drug or biological on 15 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Fiasp by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 267 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABILIFY MAINTENA as an associated drug or biological on 27924 records involving 10497 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Abilify Maintena by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Nuedexta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 4462 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Paxlovid by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO as an associated drug or biological on 28 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Austedo by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $432.92 | 20.1% | 15 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $243.87 | 11.3% | 22 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $196.75 | 9.1% | 12 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $173.41 | 8.1% | 16 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $167.04 | 7.8% | 8 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $143.90 | 6.7% | 10 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $138.30 | 6.4% | 11 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $111.49 | 5.2% | 1 | 2025 |
| Mannkind Corporation | Unresolved — no canonical attribution shown | $90.90 | 4.2% | 3 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $71.72 | 3.3% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $66.58 | 3.1% | 3 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $55.02 | 2.6% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $45.58 | 2.1% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $37.89 | 1.8% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $34.53 | 1.6% | 2 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $34.04 | 1.6% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $22.52 | 1.1% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $21.98 | 1.0% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $17.95 | 0.8% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $16.86 | 0.8% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $14.90 | 0.7% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $13.60 | 0.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,997.76 | 118 |
| Education | $153.99 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $396.43 | 13 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $196.75 | 12 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $173.41 | 16 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $169.64 | 1 | 2025 |
Source payment records
|
|||||
| LOKELMA Normalized: lokelma |
Drug | AstraZeneca Pharmaceuticals LP | $169.64 | 1 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $167.04 | 8 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $135.56 | 13 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $127.34 | 11 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $105.04 | 8 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $91.57 | 7 | 2025 |
Source payment records
|
|||||
| AFREZZA Normalized: afrezza |
Drug | Mannkind Corporation | $90.90 | 3 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $71.72 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $66.58 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $50.56 | 5 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $45.58 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $45.58 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $42.18 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $42.18 | 4 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $38.86 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $37.89 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $37.89 | 2 | 2025 |
Source payment records
|
|||||
| BRILINTA Normalized: brilinta |
Drug | AstraZeneca Pharmaceuticals LP | $36.49 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $34.53 | 2 | 2025 |
Source payment records
|
|||||
| Prolastin-C Liquid Normalized: prolastin c liquid |
Biological | Grifols USA, LLC | $34.04 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $31.55 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $28.39 | 3 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $25.51 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $25.51 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $25.51 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAMAX Normalized: vyndamax |
Drug | PFIZER INC. | $24.69 | 1 | 2025 |
Source payment records
|
|||||
| VOWST Normalized: vowst |
Biological | Aimmune Therapeutics, Inc. | $22.52 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $21.98 | 2 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $17.38 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $16.86 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $14.90 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $12.77 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 66 | exact normalized | Medicare Part D |
| AREXVY arexvy |
2025 | Arexvy | 2024 | 24 | exact normalized | Medicare Part D |
| BRILINTA brilinta |
2025 | Brilinta | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| CREON creon |
2025 | Creon | 2024 | 84 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 4462 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 498 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 736 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 140 | exact normalized | Medicare Part D |
| LOKELMA lokelma |
2025 | Lokelma | 2024 | 28 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 79 | exact normalized | Medicare Part D |
| OTEZLA otezla |
2025 | Otezla | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 267 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 47 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 206 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
84 | 18 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
140 | 30 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
68 | 20 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | OTEZLA open payments reported associated product |
CMS Open Payments — General Payments 177267 supporting records · 48600 recipient NPIs · example record 1226871616 |
Otezla · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
498 | 81 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
28 | 13 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
58 | 16 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
736 | 127 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
4462 | 518 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
24 | 24 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
28 | 25 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
206 | 45 |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | INVEGA SUSTENNA open payments reported associated product |
CMS Open Payments — General Payments 39068 supporting records · 11966 recipient NPIs · example record 1174223262 |
Invega Sustenna · 2024 Exact normalized brand match · 1 Part D row |
52 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
687 | 85 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
736 | 127 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
79 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
273 | 47 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | ABILIFY MAINTENA open payments reported associated product |
CMS Open Payments — General Payments 2902 supporting records · 986 recipient NPIs · example record 1251759994 |
Abilify Maintena · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Fiasp open payments reported associated product |
CMS Open Payments — General Payments 15 supporting records · 15 recipient NPIs · example record 1188262936 |
Fiasp · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
267 | 52 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | ABILIFY MAINTENA open payments reported associated product |
CMS Open Payments — General Payments 27924 supporting records · 10497 recipient NPIs · example record 1227267721 |
Abilify Maintena · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
66 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
66 | 64 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
4462 | 518 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
35 | 34 |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 15 recipient NPIs · example record 1247249192 |
Austedo · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 8809 | 1361 |
| Amlodipine Besylate | Amlodipine Besylate | 5376 | 806 |
| Eliquis | Apixaban | 4462 | 518 |
| Levothyroxine Sodium | Levothyroxine Sodium | 3770 | 518 |
| Furosemide | Furosemide | 3743 | 608 |
| Pantoprazole Sodium | Pantoprazole Sodium | 3637 | 664 |
| Gabapentin | Gabapentin | 3203 | 508 |
| Sertraline Hcl | Sertraline Hcl | 2803 | 334 |
| Metoprolol Tartrate | Metoprolol Tartrate | 2740 | 429 |
| Mirtazapine | Mirtazapine | 2651 | 395 |
| Potassium Chloride | Potassium Chloride | 2646 | 467 |
| Lisinopril | Lisinopril | 2545 | 389 |
| Tamsulosin Hcl | Tamsulosin Hcl | 2537 | 396 |
| Donepezil Hcl | Donepezil Hcl | 2397 | 298 |
| Metoprolol Succinate | Metoprolol Succinate | 2370 | 443 |
| Trazodone Hcl | Trazodone Hcl | 2184 | 362 |
| Losartan Potassium | Losartan Potassium | 2069 | 396 |
| Omeprazole | Omeprazole | 2051 | 334 |
| Metformin Hcl | Metformin Hcl | 1887 | 302 |
| Carvedilol | Carvedilol | 1821 | 270 |
| Quetiapine Fumarate | Quetiapine Fumarate | 1772 | 240 |
| Buspirone Hcl | Buspirone Hcl | 1659 | 236 |
| Divalproex Sodium | Divalproex Sodium | 1586 | 187 |
| Hydralazine Hcl | Hydralazine Hcl | 1509 | 252 |
| Levetiracetam | Levetiracetam | 1494 | 162 |
| Memantine Hcl | Memantine Hcl | 1442 | 204 |
| Escitalopram Oxalate | Escitalopram Oxalate | 1425 | 208 |
| Clopidogrel | Clopidogrel Bisulfate | 1270 | 214 |
| Spironolactone | Spironolactone | 1201 | 264 |
| Duloxetine Hcl | Duloxetine Hcl | 1141 | 169 |
| Famotidine | Famotidine | 1072 | 173 |
| Allopurinol | Allopurinol | 1062 | 186 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 983 | 204 |
| Risperidone | Risperidone | 974 | 89 |
| Torsemide | Torsemide | 923 | 188 |
| Olanzapine | Olanzapine | 811 | 125 |
| Baclofen | Baclofen | 790 | 105 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 766 | 290 |
| Citalopram Hbr | Citalopram Hydrobromide | 748 | 113 |
| Hydrochlorothiazide | Hydrochlorothiazide | 740 | 124 |
| Jardiance | Empagliflozin | 736 | 127 |
| Warfarin Sodium | Warfarin Sodium | 735 | 78 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 731 | 186 |
| Finasteride | Finasteride | 712 | 140 |
| Simvastatin | Simvastatin | 695 | 108 |
| Xarelto | Rivaroxaban | 687 | 85 |
| Doxazosin Mesylate | Doxazosin Mesylate | 659 | 155 |
| Midodrine Hcl | Midodrine Hcl | 646 | 118 |
| Pravastatin Sodium | Pravastatin Sodium | 635 | 97 |
| Montelukast Sodium | Montelukast Sodium | 613 | 116 |
| Latanoprost | Latanoprost | 600 | 159 |
| Prednisone | Prednisone | 593 | 197 |
| Benztropine Mesylate | Benztropine Mesylate | 591 | 69 |
| Januvia | Sitagliptin Phosphate | 583 | 81 |
| Lactulose | Lactulose | 568 | 78 |
| Fluoxetine Hcl | Fluoxetine Hcl | 557 | 71 |
| Tizanidine Hcl | Tizanidine Hcl | 550 | 108 |
| Aripiprazole | Aripiprazole | 544 | 75 |
| Ondansetron Hcl | Ondansetron Hcl | 518 | 275 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 518 | 71 |
| Cephalexin | Cephalexin | 504 | 259 |
| Farxiga | Dapagliflozin Propanediol | 498 | 81 |
| Topiramate | Topiramate | 490 | 54 |
| Fluticasone Propionate | Fluticasone Propionate | 470 | 205 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 468 | 74 |
| Colchicine | Colchicine | 466 | 90 |
| Clonidine Hcl | Clonidine Hcl | 447 | 65 |
| Ezetimibe | Ezetimibe | 447 | 81 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 446 | 93 |
| Glimepiride | Glimepiride | 445 | 82 |
| Amiodarone Hcl | Amiodarone Hcl | 443 | 93 |
| Methocarbamol | Methocarbamol | 418 | 115 |
| Oxycodone Hcl | Oxycodone Hcl | 412 | 103 |
| Atenolol | Atenolol | 404 | 60 |
| Glipizide | Glipizide | 403 | 65 |
| Nystatin | Nystatin | 395 | 182 |
| Alendronate Sodium | Alendronate Sodium | 393 | 73 |
| Meloxicam | Meloxicam | 391 | 95 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 388 | 150 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 388 | 164 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 381 | 62 |
| Entresto | Sacubitril/Valsartan | 377 | 57 |
| Lamotrigine | Lamotrigine | 376 | 48 |
| Doxycycline Hyclate | Doxycycline Hyclate | 373 | 212 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 371 | 254 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 370 | 49 |
| Diclofenac Sodium | Diclofenac Sodium | 363 | 152 |
| Digoxin | Digoxin | 355 | 59 |
| Tradjenta | Linagliptin | 351 | 34 |
| Enoxaparin Sodium | Enoxaparin Sodium | 350 | 45 |
| Myrbetriq | Mirabegron | 334 | 43 |
| Bupropion Xl | Bupropion Hcl | 322 | 51 |
| Tramadol Hcl | Tramadol Hcl | 317 | 88 |
| Oxybutynin Chloride | Oxybutynin Chloride | 313 | 45 |
| Propranolol Hcl | Propranolol Hcl | 311 | 44 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 304 | 72 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 300 | 90 |
| Haloperidol | Haloperidol | 299 | 44 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 298 | 58 |
| Ropinirole Hcl | Ropinirole Hcl | 289 | 45 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 283 | 53 |
| Oxcarbazepine | Oxcarbazepine | 280 | 27 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 273 | 58 |
| Trulicity | Dulaglutide | 273 | 47 |
| Ozempic | Semaglutide | 267 | 52 |
| Hydrocortisone | Hydrocortisone | 266 | 131 |
| Venlafaxine Hcl | Venlafaxine Hcl | 266 | 32 |
| Pregabalin | Pregabalin | 263 | 45 |
| Paroxetine Hcl | Paroxetine Hcl | 259 | 32 |
| Sevelamer Carbonate | Sevelamer Carbonate | 258 | 41 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 254 | 70 |
| Divalproex Sodium Er | Divalproex Sodium | 253 | 34 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 240 | 49 |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 239 | 29 |
| Novolog Flexpen | Insulin Aspart | 237 | 41 |
| Metformin Hcl Er | Metformin Hcl | 234 | 47 |
| Humalog Kwikpen U-100 | Insulin Lispro | 216 | 77 |
| Ibuprofen | Ibuprofen | 206 | 91 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 206 | 45 |
| Meclizine Hcl | Meclizine Hcl | 203 | 62 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 202 | 104 |
| Humalog | Insulin Lispro | 197 | 63 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 193 | 125 |
| Azithromycin | Azithromycin | 191 | 153 |
| Carbamazepine | Carbamazepine | 191 | 23 |
| Diltiazem Hcl | Diltiazem Hcl | 189 | 27 |
| Lorazepam | Lorazepam | 179 | 52 |
| Cefdinir | Cefdinir | 176 | 135 |
| Nifedipine Er | Nifedipine | 174 | 38 |
| Ketoconazole | Ketoconazole | 172 | 62 |
| Albuterol Sulfate | Albuterol Sulfate | 171 | 63 |
| Enulose | Lactulose | 169 | 30 |
| Brimonidine Tartrate | Brimonidine Tartrate | 168 | 42 |
| Fluconazole | Fluconazole | 161 | 97 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 160 | 99 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 159 | 38 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 159 | 45 |
| Bupropion Hcl Sr | Bupropion Hcl | 152 | 26 |
| Lovastatin | Lovastatin | 152 | 24 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 152 | 20 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 147 | 57 |
| Valsartan | Valsartan | 147 | 25 |
| Chlorthalidone | Chlorthalidone | 146 | 25 |
| Timolol Maleate | Timolol Maleate | 146 | 44 |
| Ranolazine Er | Ranolazine | 144 | 27 |
| Loperamide | Loperamide Hcl | 143 | 85 |
| Clozapine | Clozapine | 140 | suppressed |
| Linzess | Linaclotide | 140 | 30 |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 140 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 139 | 49 |
| Ziprasidone Hcl | Ziprasidone Hcl | 137 | 15 |
| Amitriptyline Hcl | Amitriptyline Hcl | 136 | 32 |
| Methotrexate | Methotrexate Sodium | 134 | 14 |
| Clonidine | Clonidine | 133 | 22 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 133 | 26 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 133 | 40 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 130 | 76 |
| Amoxicillin | Amoxicillin | 129 | 84 |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 129 | 35 |
| Lubiprostone | Lubiprostone | 129 | 14 |
| Primidone | Primidone | 129 | 18 |
| Rivastigmine | Rivastigmine Tartrate | 127 | 26 |
| Methenamine Hippurate | Methenamine Hippurate | 124 | 18 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 124 | 67 |
| Rivastigmine | Rivastigmine | 123 | 21 |
| Budesonide | Budesonide | 122 | 26 |
| Insulin Lispro | Insulin Lispro | 122 | 57 |
| Nortriptyline Hcl | Nortriptyline Hcl | 120 | 22 |
| Valacyclovir | Valacyclovir Hcl | 119 | 41 |
| Sucralfate | Sucralfate | 117 | 29 |
| Alprazolam | Alprazolam | 115 | 21 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 115 | 71 |
| Nitroglycerin | Nitroglycerin | 114 | 71 |
| Clonazepam | Clonazepam | 112 | 16 |
| Dicyclomine Hcl | Dicyclomine Hcl | 109 | 27 |
| Breo Ellipta | Fluticasone/Vilanterol | 108 | 24 |
| Diazepam | Diazepam | 108 | 11 |
| Folic Acid | Folic Acid | 108 | 24 |
| Trintellix | Vortioxetine Hydrobromide | 108 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 107 | 25 |
| Zolpidem Tartrate | Zolpidem Tartrate | 107 | 27 |
| Azelastine Hcl | Azelastine Hcl | 106 | 37 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 106 | 25 |
| Anastrozole | Anastrozole | 104 | 18 |
| Lacosamide | Lacosamide | 104 | suppressed |
| Fenofibrate | Fenofibrate | 101 | 14 |
| Ipratropium Bromide | Ipratropium Bromide | 101 | 26 |
| Dropsafe Pen Needle | Pen Needle, Diabetic, Safety | 100 | 39 |
| Fluphenazine Hcl | Fluphenazine Hcl | 100 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 98 | 11 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 98 | 11 |
| Naltrexone Hcl | Naltrexone Hcl | 96 | 11 |
| Paliperidone Er | Paliperidone | 96 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 95 | 23 |
| Memantine Hcl Er | Memantine Hcl | 95 | 14 |
| Calcium Acetate | Calcium Acetate | 92 | 17 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 91 | 27 |
| Lidocaine | Lidocaine | 91 | 31 |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 88 | 15 |
| Prazosin Hcl | Prazosin Hcl | 88 | 11 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 87 | 17 |
| Carbamazepine Er | Carbamazepine | 86 | suppressed |
| Cilostazol | Cilostazol | 86 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 85 | 14 |
| Creon | Lipase/Protease/Amylase | 84 | 18 |
| Letrozole | Letrozole | 84 | 11 |
| Trospium Chloride | Trospium Chloride | 84 | 19 |
| Ammonium Lactate | Ammonium Lactate | 82 | 57 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 82 | 18 |
| Calcitriol | Calcitriol | 82 | 32 |
| Novofine Autocover | Pen Needle, Diabetic, Safety | 82 | 34 |
| Ondansetron Odt | Ondansetron | 82 | 42 |
| Sps | Sodium Polystyrene Sulfon/Sorb | 82 | 48 |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 81 | suppressed |
| Amantadine | Amantadine Hcl | 80 | 13 |
| Erythromycin | Erythromycin Base | 80 | 40 |
| Mounjaro | Tirzepatide | 79 | 17 |
| Nyamyc | Nystatin | 77 | 42 |
| Prednisolone Acetate | Prednisolone Acetate | 77 | 31 |
| Verapamil Er | Verapamil Hcl | 76 | 16 |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 75 | 31 |
| Ventolin Hfa | Albuterol Sulfate | 75 | 31 |
| Glipizide Er | Glipizide | 74 | 23 |
| Incruse Ellipta | Umeclidinium Bromide | 73 | 17 |
| Acyclovir | Acyclovir | 72 | 16 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 72 | 38 |
| Diltiazem 24hr Er | Diltiazem Hcl | 71 | 14 |
| Levofloxacin | Levofloxacin | 71 | 55 |
| Olanzapine Odt | Olanzapine | 71 | 12 |
| Zonisamide | Zonisamide | 71 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 70 | 22 |
| Enalapril Maleate | Enalapril Maleate | 70 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 70 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 69 | 19 |
| Mupirocin | Mupirocin | 69 | 42 |
| Terazosin Hcl | Terazosin Hcl | 69 | 12 |
| Vascepa | Icosapent Ethyl | 69 | suppressed |
| Synthroid | Levothyroxine Sodium | 68 | 20 |
| Celecoxib | Celecoxib | 67 | 16 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 66 | 64 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 66 | 15 |
| Doxepin Hcl | Doxepin Hcl | 66 | 12 |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 66 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 65 | 12 |
| Spiriva Respimat | Tiotropium Bromide | 65 | 14 |
| Acetylcysteine | Acetylcysteine | 62 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 62 | 19 |
| Metolazone | Metolazone | 62 | 18 |
| Solifenacin Succinate | Solifenacin Succinate | 61 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 60 | 31 |
| Estradiol | Estradiol | 60 | 13 |
| Lithium Carbonate | Lithium Carbonate | 60 | suppressed |
| Sodium Bicarbonate | Sodium Bicarbonate | 60 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 59 | 12 |
| Bumetanide | Bumetanide | 59 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 59 | 44 |
| Naproxen | Naproxen | 59 | 13 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 58 | 14 |
| Methylprednisolone | Methylprednisolone | 58 | 45 |
| Sodium Chloride | 0.9 % Sodium Chloride | 58 | 26 |
| Symbicort | Budesonide/Formoterol Fumarate | 58 | 16 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 57 | 12 |
| Dexamethasone | Dexamethasone | 57 | 33 |
| Acetic Acid | Acetic Acid | 55 | 11 |
| Ibandronate Sodium | Ibandronate Sodium | 55 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 54 | suppressed |
| Methimazole | Methimazole | 53 | 15 |
| Invega Sustenna | Paliperidone Palmitate | 52 | suppressed |
| Ertapenem | Ertapenem Sodium | 51 | 18 |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 51 | 48 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 51 | suppressed |
| Heparin Sodium | Heparin Sodium,porcine | 50 | 21 |
| Raloxifene Hcl | Raloxifene Hcl | 50 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 48 | suppressed |
| Azathioprine | Azathioprine | 48 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 48 | suppressed |
| Dulera | Mometasone/Formoterol | 48 | 15 |
| Permethrin | Permethrin | 48 | 29 |
| Dapagliflozin | Dapagliflozin Propanediol | 47 | 30 |
| Entacapone | Entacapone | 47 | suppressed |
| Ingrezza | Valbenazine Tosylate | 47 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 47 | 15 |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 47 | suppressed |
| Rybelsus | Semaglutide | 47 | suppressed |
| Scopolamine | Scopolamine | 46 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 45 | 18 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 45 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 44 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 43 | suppressed |
| Steglatro | Ertugliflozin Pidolate | 42 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 41 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 41 | suppressed |
| Ramipril | Ramipril | 41 | suppressed |
| Fosfomycin Tromethamine | Fosfomycin Tromethamine | 40 | 26 |
| Metronidazole | Metronidazole | 40 | 26 |
| Rasagiline Mesylate | Rasagiline Mesylate | 40 | suppressed |
| Vraylar | Cariprazine Hcl | 40 | suppressed |
| Klayesta | Nystatin | 39 | 17 |
| Restasis | Cyclosporine | 39 | suppressed |
| Tobramycin | Tobramycin | 39 | 36 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 38 | 18 |
| Propranolol Hcl Er | Propranolol Hcl | 38 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 38 | 15 |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 37 | 11 |
| Desmopressin Acetate | Desmopressin Acetate | 37 | suppressed |
| Dofetilide | Dofetilide | 37 | suppressed |
| Irbesartan | Irbesartan | 37 | 13 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 37 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 37 | 20 |
| Spiriva Handihaler | Tiotropium Bromide | 37 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 36 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 36 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 36 | suppressed |
| Nateglinide | Nateglinide | 36 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 36 | 14 |
| Xifaxan | Rifaximin | 36 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 35 | suppressed |
| Entecavir | Entecavir | 35 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 35 | suppressed |
| Lansoprazole | Lansoprazole | 35 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 35 | suppressed |
| Novolog | Insulin Aspart | 35 | 13 |
| Paxlovid | Nirmatrelvir/Ritonavir | 35 | 34 |
| Lithium Carbonate Er | Lithium Carbonate | 34 | suppressed |
| Balsalazide Disodium | Balsalazide Disodium | 33 | suppressed |
| Ciclopirox | Ciclopirox | 33 | 15 |
| Fanapt | Iloperidone | 33 | suppressed |
| Kapspargo Sprinkle | Metoprolol Succinate | 33 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 33 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 33 | 11 |
| Risperdal Consta | Risperidone Microspheres | 33 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 33 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 32 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 32 | suppressed |
| Humulin N | Insulin Nph Human Isophane | 32 | suppressed |
| Pentoxifylline | Pentoxifylline | 32 | suppressed |
| Valproic Acid | Valproic Acid | 32 | suppressed |
| Corlanor | Ivabradine Hcl | 31 | suppressed |
| Gemfibrozil | Gemfibrozil | 31 | suppressed |
| Mirabegron Er | Mirabegron | 31 | 12 |
| Namzaric | Memantine Hcl/Donepezil Hcl | 31 | suppressed |
| Phenytoin | Phenytoin | 31 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 31 | suppressed |
| Acarbose | Acarbose | 30 | suppressed |
| Cimetidine | Cimetidine | 30 | suppressed |
| Levemir Flexpen | Insulin Detemir | 30 | 11 |
| Colesevelam Hcl | Colesevelam Hcl | 29 | suppressed |
| Febuxostat | Febuxostat | 29 | suppressed |
| Fondaparinux Sodium | Fondaparinux Sodium | 29 | suppressed |
| Humulin R | Insulin Regular, Human | 29 | suppressed |
| Hydroxyurea | Hydroxyurea | 29 | suppressed |
| Otezla | Apremilast | 29 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 28 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 28 | 13 |
| Nystop | Nystatin | 28 | 17 |
| Phenobarbital | Phenobarbital | 28 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 28 | 25 |
| Vilazodone Hcl | Vilazodone Hcl | 28 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 27 | 23 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 27 | 15 |
| Fentanyl | Fentanyl | 27 | suppressed |
| Sulfasalazine | Sulfasalazine | 27 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Ampicillin Sodium | Ampicillin Sodium | 26 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 26 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 26 | 18 |
| Guanfacine Hcl | Guanfacine Hcl | 26 | suppressed |
| Kerendia | Finerenone | 26 | suppressed |
| Klor-Con 10 | Potassium Chloride | 26 | 11 |
| Minoxidil | Minoxidil | 26 | suppressed |
| Modafinil | Modafinil | 26 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 26 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 25 | 15 |
| Novolin N | Insulin Nph Human Isophane | 25 | suppressed |
| Risperidone Odt | Risperidone | 25 | suppressed |
| Sodium Chloride | Sodium Chloride | 25 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 24 | 24 |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 24 | suppressed |
| Carbidopa-Levodopa-Entacapone | Carbidopa/Levodopa/Entacapone | 24 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 24 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 24 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 24 | suppressed |
| Admelog Solostar | Insulin Lispro | 23 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 23 | 14 |
| Exemestane | Exemestane | 23 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 23 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 23 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 22 | suppressed |
| Brilinta | Ticagrelor | 22 | suppressed |
| Gavilyte-G | Peg3350/Sod Sulf,bicarb,cl/Kcl | 22 | 20 |
| Glucagon Emergency Kit | Glucagon | 22 | 19 |
| Alogliptin | Alogliptin Benzoate | 21 | suppressed |
| Clobazam | Clobazam | 21 | suppressed |
| Klor-Con M20 | Potassium Chloride | 21 | suppressed |
| Levetiracetam Er | Levetiracetam | 21 | suppressed |
| Sotalol | Sotalol Hcl | 21 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 21 | suppressed |
| Travoprost | Travoprost | 21 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 20 | suppressed |
| Clotrimazole | Clotrimazole | 20 | 13 |
| Eplerenone | Eplerenone | 20 | suppressed |
| Gemtesa | Vibegron | 20 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 20 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 20 | suppressed |
| Abilify Maintena | Aripiprazole | 19 | suppressed |
| Alphagan P | Brimonidine Tartrate | 19 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 19 | suppressed |
| Dextrose In Water | Dextrose 5 % In Water | 19 | 13 |
| Fluorometholone | Fluorometholone | 19 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 19 | 12 |
| Haloperidol Lactate | Haloperidol Lactate | 19 | 12 |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 19 | suppressed |
| Polymyxin B Sul-Trimethoprim | Polymyxin B Sulf/Trimethoprim | 19 | suppressed |
| Premarin | Estrogens, Conjugated | 19 | suppressed |
| Qulipta | Atogepant | 19 | suppressed |
| Sodium Chloride | Sodium Chloride 0.45 % | 19 | 13 |
| Ursodiol | Ursodiol | 19 | suppressed |
| Avonex Pen (4 Pack) | Interferon Beta-1a | 18 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 18 | suppressed |
| Isosorbide Mononitrate | Isosorbide Mononitrate | 18 | suppressed |
| Levemir | Insulin Detemir | 18 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 18 | suppressed |
| Retacrit | Epoetin Alfa-Epbx | 18 | suppressed |
| Simbrinza | Brinzolamide/Brimonidine Tart | 18 | suppressed |
| Tadalafil | Tadalafil | 18 | suppressed |
| Velphoro | Sucroferric Oxyhydroxide | 18 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 17 | 12 |
| Brinzolamide | Brinzolamide | 17 | suppressed |
| Budesonide Dr | Budesonide | 17 | suppressed |
| Fiasp | Insulin Aspart (Niacinamide) | 17 | suppressed |
| Glucagen | Glucagon | 17 | 11 |
| Phenelzine Sulfate | Phenelzine Sulfate | 17 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 17 | 11 |
| Atrovent Hfa | Ipratropium Bromide | 16 | suppressed |
| Bicalutamide | Bicalutamide | 16 | suppressed |
| Edurant | Rilpivirine Hcl | 16 | suppressed |
| Estarylla | Norgestimate-Ethinyl Estradiol | 16 | suppressed |
| Haloperidol Decanoate | Haloperidol Decanoate | 16 | suppressed |
| Lidocaine Hcl Viscous | Lidocaine Hcl | 16 | suppressed |
| Methadone Hcl | Methadone Hcl | 16 | suppressed |
| Novolin R | Insulin Regular, Human | 16 | suppressed |
| Perphenazine | Perphenazine | 16 | suppressed |
| Temazepam | Temazepam | 16 | suppressed |
| Timolol Maleate | Timolol Maleate/Pf | 16 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 16 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 16 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 15 | suppressed |
| Clomipramine Hcl | Clomipramine Hcl | 15 | suppressed |
| Cyclosporine | Cyclosporine | 15 | suppressed |
| Dorzolamide-Timolol | Dorzolamide/Timolol/Pf | 15 | suppressed |
| Emtricitabine-Tenofovir Disop | Emtricitabine/Tenofovir (Tdf) | 15 | suppressed |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 15 | suppressed |
| Klor-Con M10 | Potassium Chloride | 15 | suppressed |
| Monoject Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 15 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 15 | 14 |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 15 | suppressed |
| Trospium Chloride Er | Trospium Chloride | 15 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 14 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 14 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Easy Touch Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Epinephrine | Epinephrine | 14 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 14 | suppressed |
| Ofloxacin | Ofloxacin | 14 | 14 |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 14 | suppressed |
| Repatha Sureclick | Evolocumab | 14 | suppressed |
| Rytary | Carbidopa/Levodopa | 14 | suppressed |
| Sodium Acetate | Sodium Acetate | 14 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 14 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 13 | suppressed |
| Lamotrigine Er | Lamotrigine | 13 | suppressed |
| Mesalamine Er | Mesalamine | 13 | suppressed |
| Qvar Redihaler | Beclomethasone Dipropionate | 13 | suppressed |
| Repatha Syringe | Evolocumab | 13 | suppressed |
| Ropinirole Er | Ropinirole Hcl | 13 | suppressed |
| Sodium Polystyrene Sulfonate | Sodium Polystyrene Sulfonate | 13 | suppressed |
| Tacrolimus | Tacrolimus | 13 | suppressed |
| Tamoxifen Citrate | Tamoxifen Citrate | 13 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Veltassa | Patiromer Calcium Sorbitex | 13 | suppressed |
| Victoza 3-Pak | Liraglutide | 13 | suppressed |
| Amiloride Hcl | Amiloride Hcl | 12 | suppressed |
| Arformoterol Tartrate | Arformoterol Tartrate | 12 | suppressed |
| Cefadroxil | Cefadroxil | 12 | suppressed |
| Difluprednate | Difluprednate | 12 | suppressed |
| Ibu | Ibuprofen | 12 | suppressed |
| Klor-Con | Potassium Chloride | 12 | suppressed |
| Leflunomide | Leflunomide | 12 | suppressed |
| Moxifloxacin | Moxifloxacin Hcl | 12 | suppressed |
| Multaq | Dronedarone Hcl | 12 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 12 | suppressed |
| Piperacillin-Tazobactam | Piperacillin Sodium/Tazobactam | 12 | suppressed |
| Sevelamer Hcl | Sevelamer Hcl | 12 | suppressed |
| Tiadylt Er | Diltiazem Hcl | 12 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 12 | suppressed |
| Vyzulta | Latanoprostene Bunod | 12 | suppressed |
| Austedo | Deutetrabenazine | 11 | suppressed |
| Aztreonam | Aztreonam | 11 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 11 | suppressed |
| Cholestyramine Light | Cholestyramine | 11 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Humulin N Kwikpen | Insulin Nph Human Isophane | 11 | suppressed |
| Metformin Er Osmotic | Metformin Hcl | 11 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 11 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 11 | suppressed |
| Novolin N Flexpen | Insulin Nph Human Isophane | 11 | suppressed |
| Pindolol | Pindolol | 11 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 11 | suppressed |
| Riluzole | Riluzole | 11 | suppressed |
| Rocklatan | Netarsudil Mesylat/Latanoprost | 11 | suppressed |
| Silodosin | Silodosin | 11 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,151.75 · 120 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AFREZZA, AIRSUPRA, AREXVY, BRILINTA, CAMZYOS, CAPLYTA, COMIRNATY, CREON, Dexcom G6 Transmitter, ELIQUIS, EVENITY, FARXIGA, FREESTYLE LIBRE 3, JARDIANCE, Kerendia, Korlym, LINZESS, LOKELMA, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, Prolastin-C Liquid, REPATHA, REXULTI, Rybelsus, SPRAVATO, TRELEGY ELLIPTA, VOQUEZNA, VOWST, VYNDAMAX, VYNDAQEL, ZAVZPRET, ZEPBOUND | 31 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error